Connect with us

News

MTIP closes second health tech growth fund above target

Published

on

MTIP seeks to capitalise on Europe’s rapidly expanding health tech landscape, providing up to €25m in funding to help promising scale-up companies become global leaders.

MTIP, a Swiss health tech-focused private equity firm, has announced the closing of its MTIP Fund II, SCSp at USD $250m in capital commitments.

The fund, which closed above its target of $225m, continues its predecessor fund’s strategy of investing in growing and innovative health tech companies primarily across Europe.

The fund, which is one of the few health tech-specific private equity funds focused on Europe, provides growth capital to entrepreneurial and fast-growing digital health and digitally-connected medical device companies.

MTIP Fund II is a designated ‘dark green’ fund, under Article 9 of the EU’s Sustainable Finance Disclosure Regulation, meaning its objective is to target sustainable investments.

It seeks to capitalise on Europe’s rapidly expanding health tech landscape, providing up to €25m in funding to help promising scale-up companies become global leaders.

Dr. Christoph Kausch, managing partner at MTIP, said, after a strong first closing in late March of this year, MTIP has completed the final closing of its second fund above its original target with capital raised from new and existing investors, including multiple renowned institutional investors, pension funds, family offices, hospitals, and foundations.

“We are excited to announce the successful closing of our second fund and continue our mission to build the health tech leaders of tomorrow.

“The trust our investors have put in us is a great endorsement of our strategy that’s built on our singular focus and proven approach to value creation.”

The worldwide COVID-19 pandemic has accelerated innovation in the healthcare sector and led to the adoption of new technologies.

MTIP’s investment team closely observes relevant healthcare and societal trends to source the most significant players in various markets.

MTIP streamlines an exclusive flow of investment opportunities, which is enhanced by the firm’s network, its leading role in Europe, as well as its specific strategy to invest solely in health tech companies.

The company has already made five investments out of its second fund: Oviva, Trialbee, Koa Health, Intelligencia, and Mediktor.

Dr. Andreas Schönenberger, CEO at the Swiss health insurance company Sanitas, is one of the investors in MTIP Fund II.

He said: “MTIP has unique expertise in health tech and fosters innovation in this under-served private equity sector.

“Our collaboration with MTIP gives us access to innovative health tech solutions that enable us to generate added value for our customers.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health tech alerts



Sign up for HT World updates

Copyright © 2021 Aspect Publishing Ltd.